- $36.62m
- $24.64m
- 15
- 17
- 35
- 12
Annual income statement for IN8BIO,., fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 5.13 | 8.56 | 14.7 | 28.5 | 30.3 |
Operating Profit | -5.13 | -8.56 | -14.7 | -28.5 | -30.3 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -5.13 | -8.56 | -14.7 | -28.5 | -30 |
Provision for Income Taxes | |||||
Net Income After Taxes | -5.13 | -8.56 | -14.7 | -28.5 | -30 |
Net Income Before Extraordinary Items | |||||
Net Income | -5.13 | -8.56 | -14.7 | -28.5 | -30 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -5.91 | -10.3 | -14.7 | -28.5 | -30 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.301 | -0.551 | -0.78 | -1.36 | -1 |
Dividends per Share |